Medication management in multimorbidity can require choosing among several legitimate aims rather than maximizing one clinical endpoint. Patients may value symptom control, independence, longevity, treatment simplicity, affordability, and freedom from adverse effects, while clinicians must consider safety, expected benefit, feasibility, and continuity. These aims may become mutually constraining when one medication decision advances some priorities while compromising others. This article develops a Deliberative Medication Trade-Off Model for interdisciplinary medication management. The model distinguishes identifying competing priorities, making trade-offs explicit, negotiating a provisional agreement, allocating responsibility for enactment, and documenting conditions for revisiting. It also treats disagreement and uncertainty as possible continuing states rather than defects that must always be converted into consensus. The contribution is conditional: elaborate deliberation adds little where one option is clearly dominant, unavailable, or already aligned with a stable priority. Where legitimate priorities materially conflict, however, medication decisions should be judged by whether competing aims, sacrifices, responsibilities, and conditions for revision have been made sufficiently explicit.
